Biomarkers predicting inhaled corticosteroids (ICS) and long-acting muscarinic antagonist treatment (LAMA) scores vary between adult and adolescent asthma patients, reveals the latest research by a team of scientists led by Dr Jerry A. Krishnan, associate vice chancellor for population health sciences and professor of medicine and public health at the University of Illinois. The study enrolled 295 adults and adolescents in a trial titled SIENA to find that about 20 percent of adults and 40 percent of adolescents required acute care for one or more asthma episodes in the previous year. These findings indicate that the biomarkers that predict response to ICS (or LAMA) therapy are likely to be different in adults versus adolescents and type 2 inflammatory and physiology biomarker-stratified clinical trials are needed to identify ICS or LAMA as first-line controllers specific to adults and adolescents with mild persistent asthma.